Intensity Therapeutics In... (INTS)
2.70
0.10 (3.85%)
At close: Jan 15, 2025, 1:22 PM
undefined% (undefined)
| Bid | 2.66 |
| Market Cap | 40.78M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -2.52 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.74 |
| Volume | 47,064 |
| Avg. Volume (20D) | 31,770 |
| Open | 2.73 |
| Previous Close | 2.60 |
| Day's Range | 2.36 - 2.74 |
| 52-Week Range | 1.50 - 5.94 |
| Beta | undefined |
About INTS
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & D...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2023
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INTS
Analyst Forecast
According to 3 analyst ratings, the average rating for INTS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 214.81% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
-12.34%
Intensity Therapeutics shares are trading lower. T...
Unlock content with
Pro Subscription
10 months ago ·
Source
+15.62%
Intensity Therapeutics shares are are trading higher after the company reported a year-over-year increase in FY24 EPS results.
